• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

左心耳封堵术作为伊布替尼所致出血性心包积液中抗凝剂的替代治疗方法

Left Atrial Appendage Occlusion as an Alternative to Anticoagulants in Ibrutinib-Induced Hemorrhagic Pericardial Effusion.

作者信息

Jeelani Hafiz, Sheikh Muhammad Mubbashir, Tahir Nayha, Ying Grace, Prasad Sonika, Yaremko Maryana, Gill Jashan

机构信息

Department of Medicine, Rosalind Franklin University/Chicago Medical School, North Chicago, Illinois, USA.

Department Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.

出版信息

JACC Case Rep. 2022 Jun 15;4(12):751-754. doi: 10.1016/j.jaccas.2022.01.027.

DOI:10.1016/j.jaccas.2022.01.027
PMID:35734528
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9207956/
Abstract

Bleeding tendency increases with concomitant use of ibrutinib and anticoagulants. Our patient presented with shortness of breath and was found to have a nonmalignant hemorrhagic pericardial effusion. Ibrutinib was resumed, and percutaneous left atrial appendage occlusion was performed as a substitute for the chemical anticoagulation to decrease the drug-drug interaction. ().

摘要

与依鲁替尼和抗凝剂同时使用时出血倾向会增加。我们的患者出现呼吸急促，经检查发现有非恶性出血性心包积液。恢复使用依鲁替尼，并进行经皮左心耳封堵术以替代化学抗凝，从而减少药物相互作用。（）

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85e8/9207956/210e90571f57/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85e8/9207956/8c91c72909dd/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85e8/9207956/7b076cda5fac/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85e8/9207956/0f35e9d763da/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85e8/9207956/210e90571f57/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85e8/9207956/8c91c72909dd/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85e8/9207956/7b076cda5fac/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85e8/9207956/0f35e9d763da/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85e8/9207956/210e90571f57/gr3.jpg

相似文献

1
Left Atrial Appendage Occlusion as an Alternative to Anticoagulants in Ibrutinib-Induced Hemorrhagic Pericardial Effusion.左心耳封堵术作为伊布替尼所致出血性心包积液中抗凝剂的替代治疗方法
JACC Case Rep. 2022 Jun 15;4(12):751-754. doi: 10.1016/j.jaccas.2022.01.027.
2
Non hemorrhagic pericardial effusion from ibrutinib İn a patient without comorbidities.在一名无合并症患者中，依鲁替尼引起的非出血性心包积液
J Oncol Pharm Pract. 2022 Jun;28(4):972-974. doi: 10.1177/10781552211073885. Epub 2022 Jan 10.
3
Left Atrial Appendage Occlusion as an Alternative to Anticoagulants in Ibrutinib-Induced Hemorrhagic Pericardial Effusion.在依鲁替尼诱导的出血性心包积液中，左心耳封堵术作为抗凝剂的替代方法
JACC Case Rep. 2022 Jun 15;4(12):755-757. doi: 10.1016/j.jaccas.2022.04.015.
4
Percutaneous left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation and contraindication for anticoagulation.经皮左心耳封堵术用于房颤且有抗凝禁忌证患者的卒中预防
Rev Neurol (Paris). 2015 May;171(5):426-32. doi: 10.1016/j.neurol.2014.11.009. Epub 2015 Apr 23.
5
Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation.接受伊布替尼和治疗性抗凝治疗的慢性淋巴细胞白血病患者的大出血发生率。
Leuk Lymphoma. 2023 Sep;64(9):1554-1561. doi: 10.1080/10428194.2023.2223740. Epub 2023 Jun 15.
6
Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.布鲁顿酪氨酸激酶抑制剂可抑制慢性淋巴细胞白血病中 FcγRIIA 介导的血小板对细菌的反应。
Front Immunol. 2021 Nov 29;12:766272. doi: 10.3389/fimmu.2021.766272. eCollection 2021.
7
Five-Year Outcomes and Cardiac Remodeling Following Left Atrial Appendage Occlusion.左心耳封堵术后 5 年的结果和心脏重构。
Clin Interv Aging. 2021 Apr 19;16:655-663. doi: 10.2147/CIA.S296639. eCollection 2021.
8
Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation.左心耳封堵术与直接口服抗凝剂在伴有心房颤动的高危患者中的比较。
J Am Coll Cardiol. 2020 Jun 30;75(25):3122-3135. doi: 10.1016/j.jacc.2020.04.067.
9
Ibrutinib-Associated Cardiac Tamponade with Concurrent Antiplatelet Therapy.依鲁替尼相关的心包填塞合并抗血小板治疗
Case Rep Hematol. 2020 Mar 27;2020:4282486. doi: 10.1155/2020/4282486. eCollection 2020.
10
Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.GDC-0853 对 C481S 布鲁顿酪氨酸激酶的非共价抑制：伊布替尼耐药 CLL 的新治疗策略。
Blood. 2018 Sep 6;132(10):1039-1049. doi: 10.1182/blood-2017-10-809020. Epub 2018 Jul 17.

引用本文的文献

1
Risk of drug-induced pericardial effusion: a disproportionality analysis of the FAERS database.药物性心包积液的风险：对FDA不良事件报告系统（FAERS）数据库的不成比例性分析
BMC Pharmacol Toxicol. 2025 Feb 7;26(1):27. doi: 10.1186/s40360-025-00867-6.
2
Hemorrhagic Pericardial Effusion From Apixaban Use: Case Report and Literature Review.阿哌沙班使用导致出血性心包积液：病例报告与文献综述
Cureus. 2022 Oct 7;14(10):e30021. doi: 10.7759/cureus.30021. eCollection 2022 Oct.
3
Left Atrial Appendage Occlusion as an Alternative to Anticoagulants in Ibrutinib-Induced Hemorrhagic Pericardial Effusion.

本文引用的文献

1
Ibrutinib-Associated Cardiac Tamponade with Concurrent Antiplatelet Therapy.依鲁替尼相关的心包填塞合并抗血小板治疗
Case Rep Hematol. 2020 Mar 27;2020:4282486. doi: 10.1155/2020/4282486. eCollection 2020.
2
Acute haemorrhagic tamponade in cancer patients receiving direct oral anticoagulant: case series.接受直接口服抗凝剂治疗的癌症患者发生急性出血性心包填塞：病例系列
Eur Heart J Case Rep. 2017 Dec 20;1(2):ytx018. doi: 10.1093/ehjcr/ytx018. eCollection 2017 Dec.
3
Cardiovascular Side Effects of Tyrosine Kinase Inhibitor Ibrutinib (Imbruvica) and Interaction With Direct Oral Anticoagulant.
在依鲁替尼诱导的出血性心包积液中，左心耳封堵术作为抗凝剂的替代方法
JACC Case Rep. 2022 Jun 15;4(12):755-757. doi: 10.1016/j.jaccas.2022.04.015.
酪氨酸激酶抑制剂伊布替尼（亿珂）的心血管副作用及其与直接口服抗凝剂的相互作用
Am J Ther. 2018 Nov/Dec;25(6):e768-e769. doi: 10.1097/MJT.0000000000000775.
4
Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax.慢性淋巴细胞白血病治疗中的药代动力学和药效学考虑因素：伊布替尼、idelalisib 和 venetoclax。
Clin Pharmacokinet. 2017 Nov;56(11):1255-1266. doi: 10.1007/s40262-017-0529-1.
5
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.初治和既往接受过治疗的慢性淋巴细胞白血病（CLL）和小淋巴细胞淋巴瘤（SLL）患者接受单药伊布替尼治疗的三年随访
Blood. 2015 Apr 16;125(16):2497-506. doi: 10.1182/blood-2014-10-606038. Epub 2015 Feb 19.
6
Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions.伊布替尼治疗影响胶原和血管性血友病因子依赖的血小板功能。
Blood. 2014 Dec 18;124(26):3991-5. doi: 10.1182/blood-2014-06-583294. Epub 2014 Oct 10.
7
Apixaban for extended treatment of venous thromboembolism.阿哌沙班用于静脉血栓栓塞症的延长治疗。
N Engl J Med. 2013 Feb 21;368(8):699-708. doi: 10.1056/NEJMoa1207541. Epub 2012 Dec 8.
8
Tec regulates platelet activation by GPVI in the absence of Btk.在缺乏Btk的情况下，Tec通过糖蛋白VI（GPVI）调节血小板活化。
Blood. 2003 Nov 15;102(10):3592-9. doi: 10.1182/blood-2003-04-1142. Epub 2003 Jul 3.
9
A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen.布鲁顿酪氨酸激酶（Btk）在胶原蛋白介导的血小板激活中的作用。
Curr Biol. 1998 Oct 8;8(20):1137-40. doi: 10.1016/s0960-9822(98)70471-3.